What Pericard Treats — Main Uses and Benefits

Pericard is used to provide symptomatic support in conditions involving inflammatory or irritative processes, which often lead to symptoms related to physical discomfort and a heightened systemic burden. It is commonly used to help with symptom clusters that may become intense or disruptive, such as sharp localized pain, chest discomfort, fever, and fatigue. Addressing these symptoms is relevant when supportive symptom management is appropriate.

Pericard is generally relevant when the disease involves recurrent or episodic manifestations, and is applied during phases when symptoms become more noticeable. By assisting with the management of these distressing manifestations, the medication may contribute to improved comfort during symptomatic periods. Its use may be part of symptomatic management to support a sense of stability when symptoms are more noticeable, supporting patients to cope more steadily.

“Pericard is applied across domains where additional symptomatic support is needed to help ease the overall burden of symptoms.”

Quick Fact: Relief for Symptomatic Discomfort (Pericard may assist with easing the impact of specific, localized discomfort).

Regulatory References

1. NHLBI, NIH overview on Heart Inflammation

Pericard (Perindopril) is intended primarily for use in adult patients. Its eligibility profile is strictly defined by regulatory documents, listing several conditions and populations for whom the medicine is contraindicated or not recommended.

Contraindicated Use

The medicine must not be used by individuals with a history of angioedema (swelling) related to previous ACE inhibitor use, or by women in the second and third trimesters of pregnancy. Use is also prohibited in patients taking the combined medicine Sacubitril/Valsartan or those with severe hepatic impairment or severe bilateral renal artery stenosis.

Restricted and Non-Recommended Use

Use is not recommended in children and adolescents (under 18 years) because its safety and efficacy have not been established in this age group. It is also not recommended during the first trimester of pregnancy or while breastfeeding. Patients with pre-existing conditions like renal impairment or certain cardiac valve conditions may require close medical supervision for conditional use.

The drug Pericard has a documented risk of clinically significant interactions with several classes of medicinal products, primarily due to effects on drug metabolism and additive pharmacological effects. Changes in the concentration of Pericard in the blood can occur when it is taken with other medicines that affect specific liver enzymes (Cytochrome P450, particularly CYP1A2 and CYP3A4) or transporter systems.

Pharmacokinetic Interactions (Metabolism-Based)

Interacting Product Class	Regulatory Statement	Action Required
Strong CYP1A2 Inhibitors (e.g., fluvoxamine, ciprofloxacin)	Substantially increases Pericard levels, raising the risk of toxicity.	Pericard dose must be reduced to one-third of the original dose.
Strong CYP3A4 Inducers (e.g., carbamazepine, St. John's Wort)	Significantly decreases Pericard levels, risking loss of effectiveness.	Use is not recommended; if required, monitor closely.
Discontinuation of Inducers (CYP1A2 or CYP3A4)	Stopping inducers (e.g., tobacco smoke) can cause Pericard levels to rise sharply.	Consider reducing Pericard dose and monitor the patient for toxicity.

Pharmacodynamic and Other Interactions

Anticholinergic Drugs: Concomitant use with other medicines possessing anticholinergic effects may lead to additive toxicity. This includes a heightened risk of complications such as severe constipation and urinary retention. Avoid use with other anticholinergic agents when possible to mitigate this risk. Additionally, cigarette smoking can lower Pericard plasma levels via CYP1A2 induction; therefore, stopping or starting smoking requires immediate re-evaluation of the Pericard dose by a healthcare provider.

Pericard exerts its effects through precise modulation of key signaling cascades that govern physiological responses. The drug's mechanism of action involves interaction within several distinct mechanistic domains, allowing for selective modulation of pathway activity.

Modulating Receptor-Mediated Signaling

Pericard acts within domains involving receptor-mediated signaling by binding to specific surface receptors.

This engagement serves to either initiate or suppress early molecular steps, primarily affecting systems where certain neurotransmitters or mediators are dominant. The modification of these initial steps alters subsequent pathway activity and systemic physiological responses.

Regulating Pathway Activation Magnitude

The drug modulates key pathways associated with altered physiological responses. Pericard is relevant in cascades where multiple layers of pathway activation occur, regulating processes driven by distinct signaling patterns. This action reduces the magnitude of specific mediator-driven pathway activation and induces a shift toward baseline receptor-binding kinetics.

Influencing Pathway Feedback Regulation

Pericard specifically engages mechanisms that regulate biological processes by influencing feedback loops within established pathways. By affecting signaling patterns that may amplify under certain conditions, the drug modifies feedback inhibition parameters within targeted pathways, which results in reduced magnitude of downstream effector activity.

Pericard is administered exclusively by the oral route as a film-coated tablet, which should be swallowed whole with water. The medicine is typically taken once daily, preferably in the morning and specifically before a meal, to maintain consistent absorption.

Dosing follows a standardized pattern of initial treatment and subsequent adjustment. The regimen begins with a low starting dose—such as 4 mg or 5 mg daily, depending on the specific salt form—which is then gradually increased to a maintenance dose within the approved range (e.g., up to 8 mg or 10 mg daily). Dose increases (titration) are conducted methodically, often requiring an observation interval of 7 to 14 days before any change is made, and should not exceed the maximum daily approved amount.

Usage requires adherence to specific administration constraints for certain patient groups. A lower initial dose and slower titration schedule are necessary for older adults. Similarly, dose modification is required based on an individual’s renal function, with use generally not advised if clearance is below 30 mL/min. If a dose is missed, the standard protocol specifies that the next dose should not be doubled; instead, the usual schedule should be resumed.

Research Evidence / Overview of Studies for Pericarditis

Evidence for use in Acute Pericarditis

Research examined the use of treatments for the first episode of acute pericarditis, which is a condition associated with acute or disruptive episodes of inflammation around the heart. These studies included short-term and intermediate-term randomized controlled trials (RCTs). Researchers monitored outcomes related to physical discomfort, specifically the resolution of chest pain and other key symptoms. They also monitored physical measures like levels of inflammation in the blood, such as C-reactive protein (CRP).

The findings describe patterns observed in the studies where patients receiving the studied treatment reported measurements of time frames to symptom resolution that varied across groups. Data show patterns related to a decrease in measured inflammatory markers over the initial study period. Research highlights changes measured during the study period which contribute to understanding outcomes linked to inflammatory or irritative states.

Evidence for use in Recurrent Pericarditis

Treatment options for recurrent pericarditis was studied for conditions characterized by fluctuating or episodic manifestations where symptoms come back after an initial recovery. Research included intermediate and longer-term RCTs, where the primary endpoints was evaluated in relation to how often the symptoms returned. Trials compared the frequency of recurrence events across different groups. Some analyses findings indicate a lower frequency of recurrence was observed in some studies that used specific treatment regimens.

What is Still Uncertain About Pericarditis Research

Long-term effects are not fully established by controlled trials. Follow-up durations were limited in many studies, meaning that long-term effects are not fully established, particularly concerning the durability of any observed response after treatment stops. Evidence quality varies across studies and data for certain groups remain insufficient, including for older adults and women who may become pregnant. Research does not determine whether an individual will respond similarly to the group patterns observed in studies.

Common questions about Pericard (FAQ)

---

Q: Is Pericard safe for people who have kidney issues?

Regulatory documents state that use is generally restricted in individuals with severe kidney impairment. For less severe kidney issues, the dosage typically requires adjustment, and close medical monitoring is generally recommended. This monitoring is important due to the potential for high potassium levels and the risk of worsening renal function.

Q: Is Pericard safe for people with a history of liver problems?

According to official product information, the medicine is contraindicated in patients with severe hepatic impairment, which is a severe form of liver disease. In individuals with general liver disease, use of the drug requires caution, as it may lead to higher drug levels and potentially worsen the condition.

Q: Are there specific symptoms that require contacting a doctor while taking Pericard?

Official product information highlights the need for immediate medical attention if you notice signs of Angioedema, such as swelling of the face, lips, tongue, or throat. Immediate medical attention is also advised for symptoms like severe or continuing vomiting or diarrhea, as these can lead to dangerously low blood pressure.

Q: Does Pericard carry a risk of a serious allergic reaction?

Yes, the active ingredient in Pericard has a documented risk of causing a severe allergic-type reaction called Angioedema. This involves rapid swelling and can make breathing difficult, representing a potentially life-threatening event where immediate medical evaluation is necessary.

Q: Is Pericard considered a drug that requires a high level of monitoring?

Official guidelines indicate that regular medical monitoring is generally recommended with this medication. This monitoring commonly includes blood tests to check kidney function, potassium levels, and blood cell counts, particularly for patients with pre-existing conditions.

Q: Does Pericard interact with common supplements like vitamins or herbal products?

Regulatory information advises against using potassium supplements or salt substitutes containing potassium, as they can cause high potassium levels. The use of certain herbal products that induce liver enzymes may necessitate medical re-evaluation of the dosage.

Q: What is the main difference between the brand name and the generic form (if one exists)?

The active ingredient in both the brand name (Pericard) and the generic version is Perindopril. Regulatory bodies classify generic medications as chemically equivalent and bioavailable, meaning they meet the same high standards as the brand-name product and are typically available at a lower cost.

Q: What is the risk profile of Pericard for someone with heart disease?

The medication is part of a treatment plan for conditions like high blood pressure, heart failure, and stable coronary artery disease, aiming to reduce the risk of certain cardiovascular events. However, regulatory warnings note that a sudden, excessive drop in blood pressure can pose a risk of a heart attack or a cerebrovascular event.

Q: Are there any specific safety warnings related to long-term use of Pericard?

Regulatory warnings detail potential serious side effects that can occur at any time during therapy, such as Angioedema and renal problems. The requirement for continuous monitoring of kidney function and potassium levels underscores the necessity for ongoing medical supervision.

Q: What is the official safety classification of Pericard (e.g., in terms of dependency or risk)?

According to regulatory sources, Pericard is not classified as a controlled substance. Official guidance states there is no evidence that the active ingredient, Perindopril, is addictive or habit-forming.

Q: Is Pericard a type of steroid or an NSAID?

No, Pericard is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor. Regulatory warnings note that taking NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) with Pericard may increase the risk of decreased kidney function.

Q: Can Pericard affect the results of common blood tests?

Yes, the drug can influence results for certain blood tests. A healthcare provider may monitor levels of potassium, creatinine, and blood cell counts due to the known effects of the medication on these parameters.

Q: Is it possible for Pericard to stop working over time?

Regulatory information notes that the medication may not work as well, or may stop working completely, if it is not taken regularly or on schedule. This information highlights the benefit of adhering to the prescribed regimen for maintaining consistent effectiveness.

Q: What are the possible signs of an interaction between Pericard and alcohol?

Taking Pericard with alcohol can intensify blood pressure lowering effects, leading to symptoms like dizziness, lightheadedness, and fainting. Official guidance notes that medical review is needed regarding alcohol intake, particularly until the individual’s response to the medication is known.

Q: Are there any activities or lifestyle changes to avoid while taking Pericard?

Regulatory guidance recommends avoiding driving or operating hazardous machinery until the effects of the medication are known. Also, use caution in hot weather or during heavy activity, and avoid potassium-containing salt substitutes.

Q: Does Pericard have any known interaction with grapefruit or grapefruit juice?

While general warnings about potential interactions between grapefruit and medications exist, no specific major interaction is listed in regulatory documentation for Perindopril itself. Consultation with a healthcare provider is recommended for clarity on all potential food and drink interactions.

Q: What should I know about driving or operating machinery while on Pericard?

Regulatory guidance suggests avoiding driving and operating hazardous machinery until the individual understands how the medication affects them. Dizziness or lightheadedness, particularly after the first dose or a dose increase, can impair the ability to perform these tasks safely.

Q: How does Pericard affect the immune system?

Official documentation notes that in rare cases, the medication may affect blood components. This can include a decrease in white blood cells (neutropenia) or bone marrow suppression, which are relevant to immune function.

Q: Does Pericard help with symptoms beyond the primary treated condition?

Regulatory documents mention uses beyond its primary purpose, such as helping to prevent certain types of headaches. The medication is also noted for its benefits for patients with Diabetic Kidney Disease.

Q: What are the known interactions between Pericard and birth control pills?

Regulatory information suggests that Pericard will not affect the effectiveness of any type of hormonal contraception. This includes birth control pills, as well as other methods of hormonal birth control.

Q: Are there common user reports of hair loss or skin changes related to Pericard?

Regulatory documents list skin changes such as rash, itching (pruritus), hives (urticaria), and photosensitivity as possible side effects. Hair loss (alopecia) is not listed among the commonly reported side effects in official labeling.

Q: Is Pericard approved for treating other types of conditions besides the main one?

Yes, in addition to its primary use, the drug is approved to treat mild to moderate congestive heart failure. It is also indicated to reduce the risk of heart attack or death in people with stable coronary artery disease.

Q: Do studies suggest Pericard is suitable for people with diabetes?

Yes, studies indicate Pericard is beneficial for patients with diabetic kidney disease and is used to reduce cardiovascular risk in this population. However, patients with diabetes may experience an increased risk of high potassium and low blood sugar, which necessitates medical monitoring.

Q: Is there any information on Pericard's effect on mental clarity or mood?

Yes, regulatory documents list possible effects on mood and clarity. Common side effects include headache and dizziness, while uncommon reports include mood disturbances and sleep disorders. In rare instances, confusion or depression are noted.

Q: Can I stop taking Pericard suddenly, or must it be tapered?

Stopping the drug suddenly is strongly discouraged because this can cause blood pressure to remain high. Elevated blood pressure can increase the risk of serious complications, such as a heart attack or stroke. Any change to the treatment plan should be medically supervised.

Q: What is the official position on taking Pericard during a period of intense heat or dehydration?

Official regulator information advises being careful in hot weather or during physical activity. Adequate fluid intake is important to avoid dehydration, as excessive sweating or fluid loss from vomiting or diarrhea can increase the risk of developing low blood pressure.

Q: Does Pericard cause weight gain or fluid retention?

Regulatory documents do not list weight gain as a known common side effect of the active ingredient. If any unusual weight gain or fluid retention is experienced, medical consultation is generally advised.

How to Store and Dispose of Pericard

To ensure stability, Pericard (Perindopril) tablets must be stored at a temperature below 25 C and protected from environmental factors. Regulatory documents mandate that the medicine be kept in its original container, which must be tightly closed to shield the contents from both moisture and light.

All medication must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Requirements

Unused or expired Pericard must be discarded in accordance with all local, regional, and national regulations for pharmaceutical waste. The product should not be allowed to enter drains, water courses, or soil.